Does Pulse Biosciences Inc (PLSE) Have Any Gas After Today’s Big Decline?

September 13, 2017 - By Adrian Erickson

The stock of Pulse Biosciences Inc (NASDAQ:PLSE) is a huge mover today! The stock decreased 25.60% or $3.53 during the last trading session, reaching $10.26. About 1.63 million shares traded or 727.86% up from the average. Pulse Biosciences Inc (NASDAQ:PLSE) has 0.00% since September 13, 2016 and is . It has underperformed by 16.70% the S&P500.
The move comes after 6 months negative chart setup for the $147.07 million company. It was reported on Sep, 13 by Barchart.com. We have $9.85 PT which if reached, will make NASDAQ:PLSE worth $5.88 million less.

More notable recent Pulse Biosciences Inc (NASDAQ:PLSE) news were published by: Businesswire.com which released: “Glancy Prongay & Murray LLP Commences Investigation on Behalf of Pulse …” on September 11, 2017, also Seekingalpha.com with their article: “Pulse Biosciences: Who Was In That Room?” published on August 01, 2017, Seekingalpha.com published: “Pulse Biosciences: Checking Its Pulse, Finding Nothing” on February 23, 2017. More interesting news about Pulse Biosciences Inc (NASDAQ:PLSE) were released by: Nasdaq.com and their article: “Pulse Biosciences Inc. (PLSE) Has Tumbled To A 6-Month Low” published on September 11, 2017 as well as Prnewswire.com‘s news article titled: “SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation …” with publication date: September 11, 2017.

Pulse Biosciences, Inc., formerly Electroblate, Inc., is a development-stage medical device firm using a platform technology called Nano-Pulse Electro-Signaling . The company has market cap of $147.07 million. NPES is a local and drug-free technology that utilizes nanosecond pulsed electric fields to induce cell signaling and the activation of cellular pathways in tissue. It currently has negative earnings. NPES provides treatment in a range of dermatology and aesthetic applications.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.